DURECT CorpNASDAQ:DRRX
- LAST PRICE0.9700
- TODAY'S CHANGE (%)-0.0400 (-3.9604%)
- Bid / Lots0.9800/ 50
- Ask / Lots1.1000/ 5
- Open / Previous Close1.0500 / 1.0100
- Day Range
- 52 Week Range
- Volume115,048
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DRRX |
|---|---|---|
| 09:32 ET | 5030 | 1.07 |
| 09:33 ET | 120 | 1.1038 |
| 09:35 ET | 5704 | 1.08 |
| 09:37 ET | 650 | 1.0742 |
| 09:39 ET | 12150 | 1.045 |
| 09:44 ET | 2962 | 1.0471 |
| 09:48 ET | 600 | 1.06 |
| 09:50 ET | 100 | 1.04 |
| 09:51 ET | 500 | 1.06 |
| 10:08 ET | 247 | 1.045 |
| 10:22 ET | 940 | 1.05 |
| 10:24 ET | 500 | 1.0498 |
| 10:27 ET | 2200 | 1.05 |
| 10:29 ET | 4600 | 1.05 |
| 10:31 ET | 500 | 1.045 |
| 10:33 ET | 100 | 1.05 |
| 10:36 ET | 922 | 1.0454 |
| 10:45 ET | 3200 | 1.042 |
| 10:58 ET | 100 | 1.05 |
| 11:00 ET | 1052 | 1.05 |
| 11:02 ET | 1200 | 1.05 |
| 11:03 ET | 100 | 1.05 |
| 11:05 ET | 100 | 1.045 |
| 11:07 ET | 5863 | 1.05 |
| 11:09 ET | 200 | 1.05 |
| 11:12 ET | 500 | 1.05 |
| 11:14 ET | 100 | 1.045 |
| 11:16 ET | 100 | 1.045 |
| 11:18 ET | 100 | 1.04 |
| 11:21 ET | 2100 | 1.05 |
| 11:23 ET | 100 | 1.04 |
| 11:27 ET | 100 | 1.04 |
| 11:30 ET | 100 | 1.04 |
| 11:32 ET | 900 | 1.05 |
| 11:34 ET | 100 | 1.04 |
| 11:36 ET | 100 | 1.04 |
| 11:38 ET | 2200 | 1.04 |
| 11:41 ET | 371 | 1.03 |
| 11:45 ET | 3273 | 1.03 |
| 11:50 ET | 100 | 1.01 |
| 11:56 ET | 402 | 1.01 |
| 11:57 ET | 100 | 1.01 |
| 11:59 ET | 500 | 1.02 |
| 12:03 ET | 100 | 1.02 |
| 12:08 ET | 100 | 1.01 |
| 12:10 ET | 500 | 1.0125 |
| 12:15 ET | 2480 | 1 |
| 12:17 ET | 550 | 1.03 |
| 12:24 ET | 200 | 1 |
| 12:26 ET | 100 | 1.02 |
| 12:28 ET | 100 | 1 |
| 12:33 ET | 100 | 1.015 |
| 12:42 ET | 100 | 1.02 |
| 12:44 ET | 100 | 1.015 |
| 12:51 ET | 100 | 1.015 |
| 01:02 ET | 1356 | 0.9965 |
| 01:08 ET | 500 | 0.97 |
| 01:09 ET | 100 | 0.9606 |
| 01:24 ET | 720 | 0.9965 |
| 01:26 ET | 185 | 0.9714 |
| 01:38 ET | 1625 | 0.98325 |
| 01:56 ET | 1000 | 0.98325 |
| 02:02 ET | 100 | 0.997 |
| 02:25 ET | 380 | 0.9834 |
| 02:36 ET | 100 | 0.997 |
| 02:57 ET | 100 | 0.997 |
| 03:06 ET | 8000 | 0.992 |
| 03:08 ET | 2969 | 0.9833 |
| 03:24 ET | 100 | 0.9833 |
| 03:28 ET | 100 | 1 |
| 03:39 ET | 131 | 0.9833 |
| 03:42 ET | 1021 | 0.9801 |
| 03:46 ET | 976 | 0.97 |
| 03:51 ET | 400 | 0.98 |
| 03:53 ET | 100 | 0.97 |
| 03:57 ET | 5298 | 0.9776 |
| 04:00 ET | 5838 | 0.97 |
Today
Nov 13, 2024
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones*DJ Durect 3Q Loss/Shr 14c >DRRX, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 6, 2024
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update, from 4:45PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:45PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
DURECT Corp | 31.3M | -1.7x | --- |
Tonix Pharmaceuticals Holding Corp | 35.5M | 0.0x | --- |
Curis Inc | 33.5M | -0.5x | --- |
Bolt Biotherapeutics Inc | 22.1M | -0.4x | --- |
Affimed NV | 39.9M | -0.6x | --- |
Pulmatrix Inc | 22.4M | -2.3x | --- |
Company Information
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
Contact Information
- Headquarters
- 10240 Bubb RoadCUPERTINO, CA, United States 95014
- Phone
- 408-777-1417
- Fax
- 408-777-3577
Executives
- Independent Chairman of the Board
- Gail Maderis
- President, Chief Executive Officer, Director
- James Brown
- Chief Financial Officer
- Timothy Papp
- Chief Medical Officer
- Norman Sussman
- Independent Director
- Mohammad Azab
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.3M |
|---|---|
Revenue (TTM) | $8.6M |
Shares Outstanding | 31.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-0.56 |
Book Value | $0.49 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 3.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -225.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
